Olaparib:a new drug for hereditary ovarian cancer treatment
10.3969/j.issn.1006-0111.2015.04.022
- VernacularTitle:治疗遗传性卵巢癌的新药--奥拉帕尼
- Author:
Yuenian TANG
1
;
Liang JIN
;
Chaorong SUN
Author Information
1. 上海交通大学医学院新华医院药剂科
- Keywords:
olaparib;
hereditary;
ovarian cancer
- From:
Journal of Pharmaceutical Practice
2015;(4):373-375
- CountryChina
- Language:Chinese
-
Abstract:
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes ,and was developed by AstraZen-eca Pharmaceuticals LP .Olaparib has therapeutic potential for treating cancers associated with impaired DNA repair capabili-ties ,particularly those with deficiencies in the homologous recombination repair (HRR) pathway .Olaparib is an available ther-apy option for ovarian cancer patients with deficiencies in the BRCA 1 and BRCA2 genes .Olaparib can selectively kill cancer cells without compromising normal cells .Compared to traditional chemotherapy means ,adverse reactions are much smaller .
